The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Veracyte Inc (VCYT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.04, or 0.16%, to $25.29. The Veracyte Inc has recorded 24,515 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Veracyte Announces Third Quarter 2023 Financial Results.
Veracyte Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $25.25 and fluctuated between $25.43 as its day high and $24.23 as its day low. The current market capitalization of Veracyte Inc is $1.84B. A total of 1.07 million shares were traded on the day, compared to an average of 544.88K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, VCYT has seen 1 BUY and 5 SELL insider trades, representing the acquisition of 53,182 and the disposition of 12,054 shares. Over the last 12 months, there were 22 BUYs and 43 SELLs from insiders. Insiders purchased 551,236 shares during that period but sold 405,876.
In the most recent transaction, JONES EVAN/ FA sold 3,090 shares of VCYT for 30.17 per share on Jul 19. After the transaction, the Director now owns 35,173 company shares. In a previous transaction on Jul 19, JONES EVAN/ FA sold 838 shares at 30.14 per share. VCYT shares that Director owns now total 37,601.
Among the insiders who sold shares, BISHOP JOHN L disposed of 10,000 shares on Jul 18 at a per-share price of $30.50. This resulted in the Director holding 33,125 shares of VCYT after the transaction. In another insider transaction, JONES EVAN/ FA sold 7,441 shares at $30.19 per share on Jul 18. Company shares held by the Director now total 38,263.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for VCYT in the last 3 months, the mean price target is $32.17 with high estimates of $37.00 and low estimates of $22.00. In terms of 52-week highs and lows, VCYT has a high of $32.40 and a low of $19.52.
As of this writing, VCYT has an earnings estimate of $Vanguard Intermediate-Term Corp per share for the current quarter. EPS was calculated based on a consensus of Vanguard Long-Term Corporate Bo estimates, with a high estimate of $Cyteir Therapeutics, Inc. per share and a lower estimate of $Veracyte, Inc.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VCYT’s latest balance sheet shows that the firm has $173.20M in Cash & Short Term Investments as of fiscal 2021. There were $18.85M in debt and $64.15M in liabilities at the time. Its Book Value Per Share was $14.44, while its Total Shareholder’s Equity was $1.10B.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VCYT is Buy with a score of 4.00.